Literature DB >> 1550394

Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus.

A J MacGregor1, V B Dhillon, A Binder, C A Forte, B C Knight, D J Betteridge, D A Isenberg.   

Abstract

Fasting cholesterol, triglyceride, low density lipoprotein cholesterol, high density lipoprotein cholesterol, apoprotein AI, and apoprotein B were measured in 64 patients with systemic lupus erythematosus to assess the risk factors for vascular disease. The relation between the lipid profile, steroid treatment, the presence of anticardiolipin antibodies, and the prevalence of vascular disease was examined. Raised concentrations of triglyceride and apoprotein B were seen in those patients treated with more than the equivalent of 10 mg prednisolone a day in the six months before testing. An increase in vascular disease was found only in the subgroup of patients with increased triglycerides who also expressed anticardiolipin antibodies. This study confirms the association between treatment with high doses of steroids in lupus and the development of an atherogenic plasma lipid profile. The presence of anticardiolipin antibodies compounds the risk of developing vascular disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1550394      PMCID: PMC1005648          DOI: 10.1136/ard.51.2.152

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  29 in total

1.  A comparison of autoantibodies and common DNA antibody idiotypes in SLE patients and their spouses.

Authors:  D A Isenberg; W Williams; S Le Page; G Swana; R Feldman; I Addison; R Bakimer; Y Shoenfeld
Journal:  Br J Rheumatol       Date:  1988-12

2.  Large vessel occlusion and gangrene in systemic lupus erythematosus and "lupus-like" disease. A report of six cases.

Authors:  R A Asherson; R H Derksen; E N Harris; P J Bingley; B I Hoffbrand; A E Gharavi; L Kater; G R Hughes
Journal:  J Rheumatol       Date:  1986-08       Impact factor: 4.666

3.  Changes in the platelet surface charge in rabbits with experimental hypercholesterolemia.

Authors:  C Lupu; M Calb
Journal:  Atherosclerosis       Date:  1988-07       Impact factor: 5.162

4.  Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events.

Authors:  A Hamsten; R Norberg; M Björkholm; U de Faire; G Holm
Journal:  Lancet       Date:  1986-01-18       Impact factor: 79.321

5.  Atherogenesis: a postprandial phenomenon.

Authors:  D B Zilversmit
Journal:  Circulation       Date:  1979-09       Impact factor: 29.690

6.  Immunological specificity and mechanism of action of IgG lupus anticoagulants.

Authors:  V Pengo; P Thiagarajan; S S Shapiro; M J Heine
Journal:  Blood       Date:  1987-07       Impact factor: 22.113

7.  Anticardiolipin antibodies in patients with systemic lupus erythematosus.

Authors:  G Sturfelt; O Nived; R Norberg; R Thorstensson; K Krook
Journal:  Arthritis Rheum       Date:  1987-04

8.  The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients.

Authors:  B H Bulkley; W C Roberts
Journal:  Am J Med       Date:  1975-02       Impact factor: 4.965

9.  Serum total lipids, lipoproteins cholesterol, apoproteins A and B in cardiovascular disease.

Authors:  C Vergani; G Trovato; N Dioguardi
Journal:  Clin Chim Acta       Date:  1978-07-01       Impact factor: 3.786

10.  Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids.

Authors:  W H Ettinger; A P Goldberg; D Applebaum-Bowden; W R Hazzard
Journal:  Am J Med       Date:  1987-09       Impact factor: 4.965

View more
  11 in total

Review 1.  Antiphospholipid syndrome: multiple mechanisms.

Authors:  C G Mackworth-Young
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

Review 2.  Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.

Authors:  Shipra Agrawal; Joshua J Zaritsky; Alessia Fornoni; William E Smoyer
Journal:  Nat Rev Nephrol       Date:  2017-11-27       Impact factor: 28.314

Review 3.  Why are kids with lupus at an increased risk of cardiovascular disease?

Authors:  Catherine Quinlan; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

4.  Risk factors for coronary heart disease in connective tissue diseases.

Authors:  Awal Al Husain; Ian N Bruce
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-06       Impact factor: 5.346

5.  Echocardiographic findings, lipids and lipoprotein(a) in patients with systemic lupus erythematosus.

Authors:  S Rantapää-Dahlqvist; G Neumann-Andersen; C Backman; G Dahlén; B Stegmayr
Journal:  Clin Rheumatol       Date:  1997-03       Impact factor: 2.980

6.  Management of cardiovascular complications in systemic lupus erythematosus.

Authors:  Carly Skamra; Rosalind Ramsey-Goldman
Journal:  Int J Clin Rheumtol       Date:  2010-02-01

Review 7.  Atherosclerosis and systemic lupus erythematosus.

Authors:  M Urowitz; D Gladman; I Bruce
Journal:  Curr Rheumatol Rep       Date:  2000-02       Impact factor: 4.592

Review 8.  Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

Authors:  J A P Da Silva; J W G Jacobs; J R Kirwan; M Boers; K G Saag; L B S Inês; E J P de Koning; F Buttgereit; M Cutolo; H Capell; R Rau; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

Review 9.  Imaging assessment of cardiovascular disease in systemic lupus erythematosus.

Authors:  Sara C Croca; Anisur Rahman
Journal:  Clin Dev Immunol       Date:  2011-10-23

10.  Inflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients.

Authors:  Valentina Mercurio; Antonio Lobasso; Letizia Barbieri; Paolo Parrella; Deasy Ciervo; Bianca Liccardo; Domenico Bonaduce; Carlo G Tocchetti; Amato De Paulis; Francesca W Rossi
Journal:  Int J Mol Sci       Date:  2019-04-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.